Natera presents data from Latitude MRD assay study at ESMO Congress

Natera (NTRA) announced data from a colorectal cancer study of its tissue-free Latitude MRD assay, which were presented at the 2025 European Society for Medical Oncology GI Congress. The clinical performance of the assay was analyzed in a cohort of approximately 200 patients with resectable stage I-IV colorectal cancer. Samples were derived from the GALAXY arm of the CIRCULATE-Japan study. The Latitude assay detected recurrence with 58% sensitivity in the post-surgical MRD window and 81% sensitivity in the surveillance setting, with median diagnostic lead time of 4.6 months. In the surveillance setting, patient-level specificity was 92%, and sample-level specificity was 97%. Highly prognostic of recurrence risk: MRD positivity was significantly associated with inferior outcomes during both the MRD and surveillance windows. Highly predictive of adjuvant chemotherapy benefit: Among high-risk stage II and stage III patients, those who were MRD-positive after surgery derived significant benefit from ACT, while no significant treatment benefit was observed in MRD-negative patients.